

(12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 6, 1995.

A. Federal Reserve Bank of New York (William L. Rutledge, Senior Vice President) 33 Liberty Street, New York, New York 10045:

1. *Cooperative Centrale Raiffeisen-Boerenleenbank, B.A., Rabobank Nederland*, Utrecht, The Netherlands; to engage *de novo* through its subsidiary Utrecht-America Finance Co., New York, New York, in making, acquiring, or servicing loans or other extensions of credit for the subsidiary's account, or for the account of others, such as would be made, acquired or serviced by a commercial finance company, leasing personal or real property or acting as agent, broker or advisor in leasing such property through its subsidiary, pursuant to §§ 225.25 (b)(1) and (b)(5) of the Board's Regulation Y.

B. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior

Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. *Palmer National Bancorp*, Washington, D.C.; to engage *de novo* through its subsidiary Palmer National Mortgage, Inc., Rockville, Maryland, in residential mortgage banking activities, pursuant to § 225.25(b)(1)(iii) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, January 17, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-1652 Filed 1-20-95; 8:45 am]

BILLING CODE 6210-01-F

Hibernia Corporation, et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than February 16, 1995.

A. Federal Reserve Bank of Atlanta (Zane R. Kelley, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. *Hibernia Corporation*, New Orleans, Louisiana; to merge with STABA Bancshares, Inc., Donaldsonville, Louisiana, and thereby indirectly acquire State Bank and Trust Company, Donaldsonville, Louisiana.

B. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *Goodenow Bancorporation, Inc.*, Okoboji, Iowa; to acquire 15.74 percent of the voting shares of Jackson Bancorporation, Inc., Fairmont, Minnesota, and thereby indirectly acquire Bank Midwest, Minnesota Iowa, N.A., Fairmont, Minnesota.

C. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *Community First Bankshares, Inc.*, Fargo, North Dakota; to merge with First Community Bankshares, Inc., Englewood, Colorado, and thereby indirectly acquire First National Bank at Burlington, Burlington, Colorado; Republic National Bank of Englewood, Englewood, Colorado; the First National Bank of Fort Morgan, Fort Morgan, Colorado; The First National Bank of Holyoke, Holyoke, Colorado; and the First National Bank of Sterling, Sterling, Colorado.

Board of Governors of the Federal Reserve System, January 17, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-1653 Filed 1-20-95; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee to the Director, Centers for Disease Control and Prevention (CDC); Change of Status

Federal Register Citation of Previous Announcement: 60 FR 2395—dated January 9, 1995.

SUMMARY: Notice is given that the status for the meeting of the Advisory Committee to the Director, CDC, has changed. The meeting times, date, purpose, and matters to be discussed announced in the original notice remain unchanged.

Original Status: Open to the public, limited only by the space available.

New Status: Open: 8:30 a.m.—1 p.m., Closed: 1 p.m.—2:30 p.m., Open: 2:30 p.m.—3 p.m.

Beginning at 1 p.m., through 2:30 p.m., the Advisory Committee to the Director, CDC, will meet to discuss the implications for CDC in the Administration's proposals for the fiscal year 1996 budget. An open meeting could possibly result in the premature disclosure of sensitive information concerning the 1996 Presidential budget. For this reason, this portion is exempt from mandatory disclosure

under the terms of the Government in the Sunshine Act (5 U.S.C. 552b(c)(9)(B)).

Due to programmatic issues that had to be resolved, the **Federal Register** notice amendment is being published less than fifteen days before the date of the meeting.

FOR FURTHER INFORMATION CONTACT: Martha F. Katz, Executive Secretary, Advisory Committee to the Director, CDC, 1600 Clifton Road, NE., Mailstop D-23, Atlanta, Georgia 30333, telephone 404/639-3243.

Dated: January 17, 1995.

William H. Gimson,

Acting Associate Director for Policy Coordination, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-1590 Filed 1-20-95; 8:45 am]

BILLING CODE 4163-18-M

National Committee on Vital and Health Statistics (NCVHS), Subcommittee on Mental Health Statistics, and NCVHS Subcommittee on Disability and Long-Term Care Statistics; Meetings

Pursuant to Pub. L. 92-463, the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), announces the following subcommittee meetings.

Name: NCVHS Subcommittee on Mental Health Statistics.

Time and Date: 9 a.m.-12 noon, February 7, 1995.

Place: Room 303A-305A, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201.

Status: Open.

Purpose: The Subcommittee on Mental Health Statistics will review developments in managed care and assess their implications for enrollment and encounter data sets.

Name: NCVHS Subcommittee on Mental Health Statistics and NCVHS Subcommittee on Disability and Long-Term Care Statistics.

Time and Date: 1 p.m.-5 p.m., February 7, 1995.

Place: Room 303A-305A, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201.

Status: Open.

Purpose: The Subcommittee on Mental Health Statistics and the Subcommittee on Disability and Long-Term Care Statistics will meet jointly to consider disability and health care utilization items for enrollment and encounter data sets.

Name: NCVHS Subcommittee on Disability and Long-Term Care Statistics.

Time and Date: 9:30 a.m.-12:30 p.m., February 8, 1995.

Place: Room 303A-305A, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201.

Status: Open.

Purpose: The Subcommittee on Disability and Long-Term Care Statistics will receive

presentations from staff of the Agency for Health Care Policy and Research on long-term care data in the National Medical Expenditure Survey.

FOR FURTHER INFORMATION CONTACT: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from Gail F. Fisher, Ph.D., Executive Secretary, NCVHS, NCHS, CDC, room 1100, Presidential Building, 6265 Belcrest Road, Hyattsville, Maryland 20782, telephone 301/436-7050.

Dated: January 17, 1995.

William H. Gimson,

Acting Associate Director for Policy Coordination, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-1589 Filed 1-20-95; 8:45 am]

BILLING CODE 4163-18-M

Board of Scientific Counselors, National Institute for Occupational Safety and Health; Meeting

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH).

Times and Dates: 10 a.m.-4:30 p.m., February 7, 1995. 9 a.m.-3 p.m., February 8, 1995.

Place: The Washington Court Hotel, Ash Room, 525 New Jersey Avenue NW., Washington, DC 20001.

Status: Open to the public, limited only by space available.

Purpose: The board reviews research activities to provide guidance on the quality, timeliness, and efficacy of the Institute's programs.

Matters To Be Discussed: The agenda will include the NIOSH Director's report, along with a report from the Deputy Director; a legislative review; a review of recently funded extramural research programs; agricultural program review; construction program review; final disposition of research review and training review; toxicology review; and future activities of the Board of Scientific Counselors. Agenda items are subject to change as priorities dictate. This session will be opened to the public, being limited only by space available.

FOR FURTHER INFORMATION CONTACT: Richard A. Lemen, Ph.D., Executive Secretary, BSC, NIOSH, and Deputy Director, NIOSH, CDC, 1600 Clifton Road, NE., Mailstop D-35, Atlanta, Georgia 30333, telephone 404/639-3773.

Dated: January 17, 1995.

William H. Gimson,

Acting Associate Director for Policy Coordination, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-1697 Filed 1-20-95; 8:45 am]

BILLING CODE 4163-19-M

Public Health Service

Food and Drug Administration Statement of Organization, Functions, and Delegations of Authority

Part H, Chapter HF (Food and Drug Administration) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (35 FR 3685, February 25, 1970, and 56 FR 29484, June 27, 1991, as amended most recently in pertinent part 52 FR 34851, September 15, 1987) is amended to reflect an organizational change in the Food and Drug Administration (FDA).

The positions assigned to perform the centralized investigative activities located in the Division of Ethics and Program Integrity, Office of Management, Office of Management and Systems, FDA, will be transferred to the new Office of Internal Affairs within the Office of the Commissioner. The functions and staff associated with the activities will report directly to FDA's Deputy Commissioner/Senior Advisor in the Immediate Office of the Commissioner. Since these activities could involve investigations of alleged employee misconduct anywhere in the Agency and because of the importance of providing the FDA Commissioner with an early warning of any potential misconduct, the Deputy Commissioner/Senior Advisor to the Commissioner is the appropriate person to direct these activities. Functional statements for the newly established Office of Internal Affairs are identified below.

Under section HF-B, Organization:

1. Insert a new paragraph (a-5), *Office of Internal Affairs (HFA-G)* under the Office of the Commissioner (HFA) reading as follows:

Provides a centralized Agencywide investigative resource for the Commissioner, the Deputy Commissioners, and top Agency management.

Provides a centralized investigative liaison between FDA and the Office of the Inspector General (OIG).

Serves as an FDA investigative resource to conduct internal FDA investigations and to support OIG investigations.